Patents by Inventor David Y. Jackson

David Y. Jackson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY-DRUG CONJUGATES, COMPOSITIONS AND METHODS OF USE
    Publication number: 20180147294
    Abstract: Antibody-cytotoxin antibody-drug conjugates and related compounds, such as linker-cytotoxin conjugates and the linkers used to make them, tubulysin analogs, and intermediates in their synthesis; compositions; and methods, including methods of treating cancers.
    Type: Application
    Filed: July 5, 2017
    Publication date: May 31, 2018
    Inventors: David Y. JACKSON, Edward HA, Gary D. PROBST
  • Antibody-Drug Conjugates and Related Compounds, Compositions, and Methods
    Publication number: 20160303247
    Abstract: Antibody-cytotoxin antibody-drug conjugates and related compounds, such as linker-cytotoxin conjugates and the linkers used to make them, tubulysin analogs, and intermediates in their synthesis; compositions; and methods, including methods of treating cancers.
    Type: Application
    Filed: August 24, 2015
    Publication date: October 20, 2016
    Applicant: Igenica Biotherapeutics, Inc.
    Inventors: David Y. Jackson, Edward Ha
  • Antibody-Drug Conjugates, Compositions and Methods of Use
    Publication number: 20140363454
    Abstract: Antibody-cytotoxin antibody-drug conjugates and related compounds, such as linker-cytotoxin conjugates and the linkers used to make them, tubulysin analogs, and intermediates in their synthesis; compositions; and methods, including methods of treating cancers.
    Type: Application
    Filed: June 6, 2014
    Publication date: December 11, 2014
    Applicant: Igenica Biotherapeutics, Inc.
    Inventors: David Y. Jackson, Edward Ha, Gary D. Probst
  • Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
    Patent number: 7947839
    Abstract: Bis 1,8 naphthalimide compounds including antibody drug conjugate (ADC) are described. Pharmaceutical compositions comprising an effective amount of a 1,8 bis-naphthalimide compound for treatment of hyperproliferative disorders and other disorders are described. Methods are described for killing or inhibiting the proliferation of tumor cells or cancer cells including administering to a patient an effective amount of a 1,8 bis-naphthalimide compound.
    Type: Grant
    Filed: January 30, 2006
    Date of Patent: May 24, 2011
    Assignee: Genentech, Inc.
    Inventors: Lewis J. Gazzard, Edward HyungSuk Ha, David Y. Jackson, Joann M. Um
  • TYROSINE DERIVATIVE
    Publication number: 20090325962
    Abstract: The compounds of the invention are inhibitors of alpha4 containing integrin-mediated binding to ligands such as VCAM-1 and MAdCAM.
    Type: Application
    Filed: August 21, 2009
    Publication date: December 31, 2009
    Applicant: Genentech, Inc.
    Inventors: David Y. Jackson, Frederick C. Sailes, Daniel P. Sutherlin
  • Tyrosine derivatives
    Patent number: 7595399
    Abstract: The compounds of the invention are inhibitors of alpha4 containing integrin-mediated binding to ligands such as VCAM-1 and MAdCAM.
    Type: Grant
    Filed: February 4, 2004
    Date of Patent: September 29, 2009
    Assignee: Genentech, Inc.
    Inventors: David Y. Jackson, Frederick C. Sailes, Daniel P. Sutherlin
  • MACROCYCLIC DEPSIPEPTIDE ANTIBODY-DRUG CONJUGATES AND METHODS
    Publication number: 20090226465
    Abstract: The present invention relates to antibody-drug conjugate compounds of Formula I: Ab (L D)p I where one or more macrocyclic depsipeptide drug moieties (D), selected from Aplidin, Didemnin B, Kahalalide F, and analogs and derivatives therefrom, are covalently attached by a linker (L) to an antibody (Ab) which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be useful in methods of diagnosis or treatment of cancer, and other diseases and disorders.
    Type: Application
    Filed: October 26, 2006
    Publication date: September 10, 2009
    Inventor: David Y. Jackson
  • Integrin receptor inhibitors
    Patent number: 7265146
    Abstract: Provided are compounds of formula (I) wherein A, Q, W, X, Y, Z, R1 to R4, m and n are as defined herein. Compounds of the invention bind to ?4 integrin receptors and thereby inhibit binding of ligands for ?4 integrins which is useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with ?4 integrins or their ligands.
    Type: Grant
    Filed: April 20, 2005
    Date of Patent: September 4, 2007
    Assignee: Genentech, Inc.
    Inventors: Dean R. Artis, David Y. Jackson, Thomas E. Rawson, Mark E. Reynolds, Daniel P. Sutherlin, Mark S. Stanley
  • Thiocarbamate inhibitors of alpha-4 integrins
    Patent number: 7166600
    Abstract: The invention provides novel thiocarbamate alpha-4 inhibitors of the general formula (I) that are resistant to metabolism having improved half-life and/or clearance properties compared to corresponding carbamate compounds wherein substituents L, X, Y, Z, R1–R4, m, n, o and p are as defined herein. Also provided are compositions comprising compounds of formula I and a carrier, diluent or excipient as well as methods of treating a disease or condition mediated by the binding interaction of alpha-4 integrins to its ligands such as inflammatory diseases.
    Type: Grant
    Filed: January 11, 2006
    Date of Patent: January 23, 2007
    Assignee: Genentech, Inc.
    Inventor: David Y. Jackson
  • Thiocarbamate inhibitors of alpha-4 integrins
    Patent number: 7015323
    Abstract: The invention provides novel thiocarbamate alpha-4 inhibitors of the general formula (I) that are resistant to metabolism having improved half-life and/or clearance properties compared to corresponding carbamate compounds wherein substituents L, X, Y, Z, R1–R4, m, n, o and p are as defined herein. Also provided are compositions comprising compounds of formula I and a carrier, diluent or excipient as well as methods of treating a disease or condition mediated by the binding interaction of alpha-4 integrins to its ligands such as inflammatory diseases.
    Type: Grant
    Filed: May 19, 2004
    Date of Patent: March 21, 2006
    Assignee: Genentech, Inc.
    Inventor: David Y. Jackson
  • Integrin receptor inhibitors
    Patent number: 6933314
    Abstract: Provided are compounds of formula (I) wherein A, Q, W, X, Y, Z, R1 to R4, m and n are as defined herein. Compounds of the invention bind to ?4 integrin receptors and thereby inhibit binding of ligands for ?4 integrins which is useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with ?4 integrins or their ligands.
    Type: Grant
    Filed: September 30, 2003
    Date of Patent: August 23, 2005
    Assignee: Genentech, Inc.
    Inventors: Dean R. Artis, David Y. Jackson, Thomas E. Rawson, Mark E. Reynolds, Daniel P. Sutherlin, Mark S. Stanley
  • Thiocarbamate inhibitors of alpha-4 integrins
    Publication number: 20040235750
    Abstract: The invention provides novel thiocarbamate alpha-4 inhibitors of the general formula (I) that are resistant to metabolism having improved half-life and/or clearance properties compared to corresponding carbamate compounds wherein substituents L, X, Y, Z, R1-R4, m, n, o and p are as defined herein. Also provided are compositions comprising compounds of formula I and a carrier, diluent or excipient as well as methods of treating a disease or condition mediated by the binding interaction of alpha-4 integrins to its ligands such as inflammatory diseases.
    Type: Application
    Filed: May 19, 2004
    Publication date: November 25, 2004
    Applicant: Genentech, Inc.
    Inventor: David Y. Jackson
  • Tyrosine derivatives
    Publication number: 20040158076
    Abstract: The compounds of the invention are inhibitors of alpha4 containing integrin-mediated binding to ligands such as VCAM-1 and MAdCAM.
    Type: Application
    Filed: February 4, 2004
    Publication date: August 12, 2004
    Applicant: Genentech, Inc.
    Inventors: David Y. Jackson, Frederick C. Sailes, Daniel P. Sutherlin
  • Tyrosine derivatives
    Publication number: 20040110753
    Abstract: The compounds of the invention are inhibitors of alpha4 containing integrin-mediated binding to ligands such as VCAM-1 and MAdCAM.
    Type: Application
    Filed: July 16, 2002
    Publication date: June 10, 2004
    Applicant: Genentech, Inc.
    Inventors: David Y. Jackson, Frederick C. Sailes, Daniel P. Sutherlin
  • Integrin receptor inhibitors
    Publication number: 20040077693
    Abstract: Provided are compounds of formula (I) 1
    Type: Application
    Filed: September 30, 2003
    Publication date: April 22, 2004
    Applicant: Genentech, Inc.
    Inventors: Dean R. Artis, David Y. Jackson, Thomas E. Rawson, Mark E. Reynolds, Daniel P. Sutherlin, Mark S. Stanley
  • Integrin receptor inhibitors
    Patent number: 6706753
    Abstract: Provided are compounds of formula (I) wherein A, Q, W, X, Y, Z, R1 to R4, m and n are as defined herein. Compounds of the invention bind to &agr;4 integrin receptors and thereby inhibit binding of ligands for &agr;4 integrins which is useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with &agr;4 integrins or their ligands.
    Type: Grant
    Filed: December 6, 2002
    Date of Patent: March 16, 2004
    Assignee: Genentech, Inc.
    Inventors: Dean R. Artis, David Y. Jackson, Thomas E. Rawson, Mark E. Reynolds, Daniel P. Sutherlin, Mark S. Stanley
  • Assay method
    Publication number: 20030129675
    Abstract: A new method for assaying the ability of a compound to block the binding of an &agr;4 integrin to a binding partner thereof provides a useful screening tool.
    Type: Application
    Filed: December 4, 2002
    Publication date: July 10, 2003
    Applicant: Genentech, Inc.
    Inventors: Dean R. Artis, David Y. Jackson, Susan Keating, Maureen Beresini
  • Integrin receptor inhibitors
    Publication number: 20030100599
    Abstract: Provided are compounds of formula (I) 1
    Type: Application
    Filed: December 6, 2002
    Publication date: May 29, 2003
    Applicant: Genentech, Inc.
    Inventors: Dean R. Artis, David Y. Jackson, Thomas E. Rawson, Mark E. Reynolds, Daniel P. Sutherlin, Mark S. Stanley
  • Tyrosine derivatives
    Patent number: 6469047
    Abstract: The compounds of the invention are inhibitors of alpha4 containing integrin-mediated binding to ligands such as VCAM-1 and MAdCAM.
    Type: Grant
    Filed: September 25, 2000
    Date of Patent: October 22, 2002
    Assignee: Genentech, Inc.
    Inventors: David Y. Jackson, Frederick C. Sailes, Daniel P. Sutherlin
  • Integrin receptor inhibitors
    Publication number: 20020035104
    Abstract: Provided are compounds of formula (I) 1
    Type: Application
    Filed: August 16, 2001
    Publication date: March 21, 2002
    Applicant: GENENTECH, INC.
    Inventors: Dean R. Artis, David Y. Jackson, Thomas E. Rawson, Mark E. Reynolds, Daniel P. Sutherlin, Mark S. Stanley